YKYuhei Kobayashi

Yuhei Kobayashi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yuhei Kobayashi has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Fractional Flow Reserve in Acute Coronary Syndrome: An Updated Systematic Review and Bayesian Meta‐Analysis

    by Edward T. Ha, Haider Shah, Cheng Zhang, Asa Phichaphop, Ori Waksman, Beni Verma, Yuhei Kobayashi, Ron Waksman, Héctor M. García‐García

    Background: The diagnostic performance of fractional flow reserve (FFR) in the setting of acute coronary syndrome (ACS) remains unclear. We sought to perform an updated systematic review and meta‐analysis investigating the performance of FFR‐guided revascularization in the setting of ACS. Methods: Two main primary comparisons tested the major adverse cardiac events (MACE) rate at 1‐year of patients treated with an FFR‐guided strategy in ACS versus chronic coronary syndrome and an FFR‐guided versus angiographic‐guided strategy in acute coronary syndrome. Treatment effect was defined as the risk difference and was estimated with Bayesian random effect model with a conservative prior of no treatment effect. Kaplan–Meier estimates and their standard deviations were retrieved to maximum accuracy from cumulative incidence function/ survival function plots for studies with censoring. Results: We found 11 eligible trials (with a total of 13 029 patients) in this systematic review. Within the FFR‐guided strategy, acute coronary syndrome was associated with an increased risk of MACE at 1 year compared with chronic coronary syndrome (risk difference (RD): 1.9%, 95% credible interval [0.2% to 3.6%]). In contrast, among patients with ACS no difference in 1‐year MACE rate was observed between angiography‐guided versus FFR‐guided complete revascularization strategy (RD=0.9%, 95% CI [−1.3 to 3.2]). Conclusions: FFR‐guided strategy of lesions in acute coronary syndrome was associated with worse 1‐year MACE compared with FFR‐guided revascularization in chronic coronary syndrome reflecting the high‐risk nature of acute coronary syndrome patients. No difference in long‐term outcomes was seen from a FFR‐guided versus angiography‐guided approach in acute coronary syndrome. Further studies are needed to better understand and optimize the use of physiology in the ACS setting.

  • Impact of Bifurcation Lesions on Outcomes After FFR-Guided PCI or CABG

    by Daimy M.M. Dillen, Hisao Otsuki, Kuniaki Takahashi, Yuhei Kobayashi, Zsolt Piroth, Nicolas Noiseux, Badih El Nakadi, Gintaras Kalinauskas, Laszlo Szekely, Giedrius Davidavičius, et al.

    BACKGROUND: In the era of first-generation drug-eluting stents and angiography-guided percutaneous coronary intervention (PCI), the presence of a bifurcation lesion was associated with adverse outcomes after PCI. In contrast, the presence of a bifurcation lesion had no impact on outcomes following coronary artery bypass grafting (CABG). Therefore, the presence of a coronary bifurcation lesion requires special attention when choosing between CABG and PCI. The aim of this study is to assess whether the presence of a bifurcation lesion still influences clinical outcomes after contemporary PCI using second-generation drug-eluting stent and fractional flow reserve (FFR) guidance versus CABG. METHODS: The randomized FAME 3 trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) compared FFR-guided PCI using current drug-eluting stents with CABG in patients with 3-vessel coronary artery disease. The prespecified key end point at 3-year follow-up was the composite of death, myocardial infarction, or stroke. In this substudy, the impact of bifurcation lesions on outcomes after FFR-guided PCI and CABG was investigated. RESULTS: The FAME 3 trial enrolled 1500 patients and 653 (45.2%) patients had at least 1 true bifurcation lesion. There was no difference in the composite of death, myocardial infarction, or stroke at the 3-year follow-up between patients with or without at least 1 true bifurcation lesion (11.6% versus 10.0%; hazard ratio, 1.17 [95% CI, 0.86–1.61]; P =0.32), regardless of revascularization strategy. The composite end point was not statistically different between FFR-guided PCI and CABG in patients with at least 1 true bifurcation lesion (hazard ratio, 1.27 [95% CI, 0.80–2.00]) or without a true bifurcation lesion (hazard ratio, 1.36 [95% CI, 0.87–2.12]), with no significant interaction ( P interaction =0.81). CONCLUSIONS: In patients with 3-vessel coronary artery disease, the presence of a true bifurcation lesion was not associated with a different treatment effect after FFR-guided PCI with contemporary drug-eluting stent versus CABG.


  • Impact of a Chronic Total Occlusion on Outcomes After FFR-Guided PCI or Coronary Bypass Surgery: A FAME 3 Substudy

    by Hisao Otsuki, Kuniaki Takahashi, Frederik M. Zimmermann, Kreton Mavromatis, Adel Aminian, Nikola Jagic, Jan-Henk E. Dambrink, Petr Kala, Philip MacCarthy, Nils Witt, et al.

    BACKGROUND: The clinical impact of a chronic total occlusion (CTO) in patients with 3-vessel coronary artery disease undergoing fractional flow reserve–guided percutaneous coronary intervention (PCI) with current-generation drug-eluting stents or coronary artery bypass grafting (CABG) is unclear. METHODS: The FAME 3 trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation 3) compared fractional flow reserve–guided PCI with CABG in patients with 3-vessel coronary artery disease. The primary end point was major adverse cardiac and cerebrovascular events, a composite of death, myocardial infarction, stroke, or repeat revascularization at 1 year. In this substudy, the 3-year outcomes were analyzed in patients with or without a CTO. RESULTS: Of the patients randomized to PCI or CABG in the FAME 3 trial, 305 (21%) had a CTO. In the PCI arm, revascularization of the CTO was attempted in 61% with a procedural success rate of 88%. The incidence of major adverse cardiac and cerebrovascular events at 3 years was not significantly different between those with or without a CTO in both the PCI (15.2% versus 20.1%; adjusted hazard ratio, 0.62 [95% CI, 0.38–1.03]; P =0.07) and the CABG (13.0% versus 12.9%; adjusted hazard ratio, 0.96 [95% CI, 0.55–1.66]; P =0.88) arms. In those without a CTO, PCI was associated with a significantly higher risk of major adverse cardiac and cerebrovascular events compared with CABG (adjusted hazard ratio, 1.61 [95% CI, 1.20–2.17]; P P =0.56; P interaction =0.31). CONCLUSIONS: The presence of a CTO did not significantly impact the treatment effect of PCI versus CABG at 3 years in patients with 3-vessel coronary artery disease. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02100722.


  • Fractional Flow Reserve–Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial

    by Frederik M. Zimmermann, Victoria Y. Ding, Nico H.J. Pijls, Zsolt Piroth, Albert H.M. van Straten, Laszlo Szekely, Giedrius Davidavicius, Gintaras Kalinauskas, Samer Mansour, Rajesh Kharbanda, et al.

    BACKGROUND: Previous studies comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) in patients with multivessel coronary disease not involving the left main have shown significantly lower rates of death, myocardial infarction (MI), or stroke after CABG. These studies did not routinely use current-generation drug-eluting stents or fractional flow reserve (FFR) to guide PCI. METHODS: FAME 3 (Fractional Flow Reserve versus Angiography for Multivessel Evaluation) is an investigator-initiated, multicenter, international, randomized trial involving patients with 3-vessel coronary artery disease (not involving the left main coronary artery) in 48 centers worldwide. Patients were randomly assigned to receive FFR-guided PCI using zotarolimus drug-eluting stents or CABG. The prespecified key secondary end point of the trial reported here is the 3-year incidence of the composite of death, MI, or stroke. RESULTS: A total of 1500 patients were randomized to FFR-guided PCI or CABG. Follow-up was achieved in >96% of patients in both groups. There was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI compared with CABG (12.0% versus 9.2%; hazard ratio [HR], 1.3 [95% CI, 0.98–1.83]; P =0.07). The rates of death (4.1% versus 3.9%; HR, 1.0 [95% CI, 0.6–1.7]; P =0.88) and stroke (1.6% versus 2.0%; HR, 0.8 [95% CI, 0.4–1.7]; P =0.56) were not different. MI occurred more frequently after PCI (7.0% versus 4.2%; HR, 1.7 [95% CI, 1.1–2.7]; P =0.02). CONCLUSIONS: At 3-year follow-up, there was no difference in the incidence of the composite of death, MI, or stroke after FFR-guided PCI with current-generation drug-eluting stents compared with CABG. There was a higher incidence of MI after PCI compared with CABG, with no difference in death or stroke. These results provide contemporary data to allow improved shared decision-making between physicians and patients with 3-vessel coronary artery disease. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02100722.


  • Open Access

    Optimization of the Hydrothermal Activation Treatment with Sodium Hydroxide Solution for the Conversion of Coal Fly Ash to Zeolite and Its Adsorption Capability of Lead (II) Ions from the Liquid Phase

    by Fumihiko Ogata, Noriaki Nagai, Mamiko Funaki, Ayako Tabuchi, Yuhei Kobayashi, Chalermpong Saenjum, Takehiro Nakamura, Naohito Kawasaki

    Coal fly ash (FA) was treated by hydrothermal activation with sodium hydroxide solution at different concentrations to optimize the conversion method. Zeolite of the sodium type is prepared from coal FA by 1, 1.5, and 3 mol/L sodium hydroxide solutions (ZE1, ZE1.5, and ZE3). These adsorbents’ morphology, crystal structure, scanning electron microscopy, Fourier transform (FT)-IR spectra, cation exchange capacity (CEC), specific surface area and pore volumes, and pHpzc were determined. An adsorption experiment was performed to evaluate the effects of contact time, pH, temperature, and coexistence. From the results, the values of CEC and specific surface area of prepared samples was in the order ZE3 < ZE1.5 < ZE1. The similar trends were observed in lead ions adsorption. In addition, our obtained data elucidate that the ion exchange with sodium ions in the interlayer ZE1 is one of the adsorption mechanisms of Pb2+ from water layer. Finally, lead ions adsorbed on ZE1 could be desorbed using a hydrochloric acid solution, showing that ZE1 could be reused as a water purification agent.


  • In-hospital outcome in patients presenting with acute coronary syndrome with left main coronary artery disease: A report from Japanese prospective multicenter percutaneous coronary intervention registry

    by Hidenori Tani, Mitsuaki Sawano, Yohei Numasawa, Yuhei Kobayashi, Masahiro Suzuki, Shigetaka Noma, Yasuyuki Shiraishi, Ikuko Ueda, Keiichi Fukuda, Shun Kohsaka


  • Long-term clinical outcomes with use of an angiotensin-converting enzyme inhibitor early after heart transplantation

    by Hiroyuki Arashi, Takuma Sato, Jon Kobashigawa, Helen Luikart, Yuhei Kobayashi, Kozo Okada, Seema Sinha, Yasuhiro Honda, Alan C. Yeung, Kiran Khush, et al.


  • Left ventricular myocardial function assessed by three‐dimensional speckle tracking echocardiography in Takotsubo cardiomyopathy

    by Yukari Kobayashi, Hiroyuki Okura, Yuhei Kobayashi, Shuichiro Fukuda, Atsushi Hirohata, Kiyoshi Yoshida

    Background: We aimed to investigate left ventricular (LV) functional recovery in Takotsubo cardiomyopathy (TC) using three‐dimensional (3D) speckle tracking echocardiography.Methods: Twenty‐one patients with TC who underwent routine and 3D echocardiography as well as electrocardiography were enrolled. 3D images were analyzed to measure 3D radial strain and area tracking (area change of each LV segment). Postsystolic shortening (PSS) or thickening (PST) was defined as a further shortening or thickening occurred after the end‐systole. 3D echocardiography and ECG were repeated at 4 weeks and 6 months later.Results: Mean age was 70.9±11.1 years, and 18 (86%) patients were female. All patients presented classical type of TC with apical ballooning. LV ejection fraction (EF) improved from 49.9±7.2 to 64.9±6.0% (P<.001) at 4 weeks without segmental wall‐motion abnormality. However, PSS or PST still existed in 43% of LV segments, and electrocardiographic abnormality was also observed in 51% at 4 weeks and disappeared at 6 months. Mean 3D radial strain decreased from baseline to 6 months at base (36.1±19.6 vs 28.0±12.6%, P=.04), whereas it increased at mid (16.2±7.2 vs 28.7±9.1%, P=.03) and the apex (8.0±4.4 vs 21.2±7.9%, P<.001). Mean area tracking increased from baseline to 6 months at mid and apex (−28.5±9.5 vs −44.5±9.6%, P<.001 for mid, and −24.2±13.0 vs −42.9±16.8%, P=.002 for the apex), while it did not change at base (−37.0±8.9 vs −41.9±9.6%, P=NS).Conclusions: Patients with TC show abnormal wall motion during acute phase. Even after LV wall‐motion recovery, subtle abnormalities of regional LV function appear to persist at 4 weeks followed by normalization at 6 months.